icon-folder.gif   Conference Reports for NATAP  
  EASL 45th Annual Meeting
April 14-18, 2010
Vienna, Austria
Back grey_arrow_rt.gif
Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of Nitazoxanide Plus Peginterferon and Ribavirin in HCV Genotype 1 Naïve Patients: Week 12 Sustained Virologic Response Rate
  Reported by Jules Levin
EASL Apr 14-18 2010 Vienna Austria
B.R. Bacon,1M.L. Shiffman,2J.K. Lim,3A. Berman,4V.K. Rustgi,5E.B. Keeffe,6,7and STEALTH C-3 Investigators 1St. Louis University Medical Center, St. Louis, MO, USA 2Liver Institute of Virginia, Bon Secours Health System, Newport News, VA, USA 3Yale University Medical Center, New Haven, CT, USA 4Florida Center for Gastroenterology, Largo, FL, USA, 5Georgetown University Medical Center, Washington, DC, USA and 6Romark Institute for Medical Research, Tampa, FL, USA and 7Stanford University Medical Center, Stanford, CA, USA